Skip to main content
. 2019 Aug 22;8(9):956. doi: 10.3390/cells8090956

Figure 9.

Figure 9

The effect of combined siGSK3β + siRTP801 on RGC survival and axon regeneration 24 days after ONC. Although (A) many Brn3a+ RGC were present after combined siGSK3β + siRTP801 treatment, (B) quantification of the number of RGC/250 µm GCL did not show any additive or synergistic effects of both siRNAs, despite individual and combination treatments being equally RGC neuroprotective. (C(i)) Many GAP43+ regenerating axons were present after combined siGSK3β + siRTP801 treatment; (C(ii)) shows a high power view of boxed region in C(i)). (D) Quantification of the number of GAP43+ axons at all measured distances beyond the lesion site showed that combined siGSK3β + siRTP801 treatment was significantly more axogenic than PBS, siEGFP, or siGSK3β alone treatment. Note that combined siGSK3β + siRTP801 was better than siRTP801 alone treatment, but the difference only became statistically significant at 800 µm. (Scale bars in A and C = 100 µm; * = p < 0.05, ** = p < 0.01; *** = p < 0.001). n = 6 eyes (from 6 rats)/treatment.